Charles E. Zogzas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Charles E. Zogzas has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Somshuvra Mukhopadhyay
The University of Texas at Austin
2 shared publications - Aaron Blaine Bowman
School of Health Sciences, Purdue University, West Lafayette, IN 47907, USA
1 shared publication - Adrian T. Keatinge-Clay
UT Austin
1 shared publication - Caleb D. Swaim
Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA
1 shared publication - Christine Kirmaier
Department of Chemistry, Washington University, St. Louis, MO 63130, USA
1 shared publication Darren C. Gay
Department of Molecular Biosciences, The University of Texas at Austin, 1 University Station A5000, Austin, TX 78712-0165, United States
1 shared publication
Latest Publications
- Open Access
- 1 July 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (31) , 15940-15957
Structural Elements in the Transmembrane and Cytoplasmic Domains of the Metal Transporter SLC30A10 Are Required for Its Manganese Efflux Activity
- 1 July 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (31) , 15940-15957
Open AccessStructural Elements in the Transmembrane and Cytoplasmic Domains of the Metal Transporter SLC30A10 Are Required for Its Manganese Efflux Activity
- 1 March 2016
- Published by Elsevier in Journal of Structural Biology
- Vol. 193 (3) , 196-205
The LINKS motif zippers trans-acyltransferase polyketide synthase assembly lines into a biosynthetic megacomplex
- 1 March 2016
- Published by Elsevier in Journal of Structural Biology
- Vol. 193 (3) , 196-205
The LINKS motif zippers trans-acyltransferase polyketide synthase assembly lines into a biosynthetic megacomplex
- 1 November 2014
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1837 (11) , 1892-1903
High yield of secondary B-side electron transfer in mutant Rhodobacter capsulatus reaction centers
- 1 November 2014
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1837 (11) , 1892-1903
High yield of secondary B-side electron transfer in mutant Rhodobacter capsulatus reaction centers
- Open Access
- 15 October 2014
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 34 (42) , 14079-14095
SLC30A10 Is a Cell Surface-Localized Manganese Efflux Transporter, and Parkinsonism-Causing Mutations Block Its Intracellular Trafficking and Efflux Activity
Manganese (Mn) is an essential metal, but elevated cellular levels are toxic and may lead to the development of an irreversible parkinsonian-like syndrome that has no treatment. Mn-induced parkinsonism generally occurs as a result of exposure to elevated Mn levels in occupational or environmental settings. Additionally, patients with compromised liver function attributable to diseases, such as cirrhosis, fail to excrete Mn and may develop Mn-induced parkinsonism in the absence of exposure to elevated Mn. Recently, a new form of familial parkinsonism was reported to occur as a result of mutations inSLC30A10. The cellular function of SLC30A10 and the mechanisms by which mutations in this protein cause parkinsonism are unclear. Here, using a combination of mechanistic and functional studies in cell culture,Caenorhabditis elegans, and primary midbrain neurons, we show that SLC30A10 is a cell surface-localized Mn efflux transporter that reduces cellular Mn levels and protects against Mn-induced toxicity. Importantly, mutations in SLC30A10 that cause familial parkinsonism blocked the ability of the transporter to traffic to the cell surface and to mediate Mn efflux. Although expression of disease-causing SLC30A10 mutations were not deleterious by themselves, neurons and worms expressing these mutants exhibited enhanced sensitivity to Mn toxicity. Our results provide novel insights into the mechanisms involved in the onset of a familial form of parkinsonism and highlight the possibility of using enhanced Mn efflux as a therapeutic strategy for the potential management of Mn-induced parkinsonism, including that occurring as a result of mutations inSLC30A10.
- 15 October 2014
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 34 (42) , 14079-14095
Open AccessSLC30A10 Is a Cell Surface-Localized Manganese Efflux Transporter, and Parkinsonism-Causing Mutations Block Its Intracellular Trafficking and Efflux Activity
Manganese (Mn) is an essential metal, but elevated cellular levels are toxic and may lead to the development of an irreversible parkinsonian-like syndrome that has no treatment. Mn-induced parkinsonism generally occurs as a result of exposure to elevated Mn levels in occupational or environmental settings. Additionally, patients with compromised liver function attributable to diseases, such as cirrhosis, fail to excrete Mn and may develop Mn-induced parkinsonism in the absence of exposure to elevated Mn. Recently, a new form of familial parkinsonism was reported to occur as a result of mutations inSLC30A10. The cellular function of SLC30A10 and the mechanisms by which mutations in this protein cause parkinsonism are unclear. Here, using a combination of mechanistic and functional studies in cell culture,Caenorhabditis elegans, and primary midbrain neurons, we show that SLC30A10 is a cell surface-localized Mn efflux transporter that reduces cellular Mn levels and protects against Mn-induced toxicity. Importantly, mutations in SLC30A10 that cause familial parkinsonism blocked the ability of the transporter to traffic to the cell surface and to mediate Mn efflux. Although expression of disease-causing SLC30A10 mutations were not deleterious by themselves, neurons and worms expressing these mutants exhibited enhanced sensitivity to Mn toxicity. Our results provide novel insights into the mechanisms involved in the onset of a familial form of parkinsonism and highlight the possibility of using enhanced Mn efflux as a therapeutic strategy for the potential management of Mn-induced parkinsonism, including that occurring as a result of mutations inSLC30A10.